Review

Stress- and antidepressant treatment-induced modifications of 5-HT₇ receptor functions in the rat brain

Krzysztof Tokarski¹, Bartosz Bobula¹, Małgorzata Grzegorzewska-Hiczwa¹, Magdalena Kusek¹, Grzegorz Hess^{1,2}

¹Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31-343 Kraków, Poland

²Institute of Zoology, Jagiellonian University, Gronostajowa 9, PL 30-387 Kraków, Poland

Correspondence: Krzysztof Tokarski, e-mail: ktok@if-pan.krakow.pl

Abstract:

This paper summarizes a series of electrophysiological studies aimed at finding the effects of the activation of 5-HT₇ receptors on neuronal excitability as well as on excitatory and inhibitory synaptic transmission in the hippocampus and in the frontal cortex of the rat. These studies demonstrated that 5-HT₇ receptors play an important role in the modulation of the activity of the hippocampal network by regulating the excitability of pyramidal cells of the CA1 area, as well as *via* their effect on GABA and glutamatergic transmission. The reactivity of 5-HT₇ receptors in the hippocampus is decreased by repeated administration of antidepressant drugs and increased by a prolonged high level of corticosterone. More importantly, administration of antidepressant drug, imipramine, prevents the occurrence of corticosterone-induced changes in the function of hippocampal 5-HT₇ receptors. It has also been found that the blockade of 5-HT₇ receptors by the selective antagonist SB 269970, lasting for a few days, causes similar changes to those observed after long-term administration of antidepressants. Thus, it seems that the pharmacological blockade of 5-HT₇ receptors produces faster effects compared to classic antidepressant drugs. A similarity between the changes in the glutamatergic transmission induced by the blockade of 5-HT₇ receptors and those caused by repeated administration of the antidepressant drug, imipramine, has also been found in the frontal cortex. It has also been shown that the changes in glutamatergic transmission and the impairment of long-term synaptic plasticity in the frontal cortex of animals subjected to repeated restraint stress are reversed by the blockade of 5-HT₇ receptors.

Overall, these studies, together with the data provided by other investigators, support the hypothesis that 5-HT₇ receptor antagonists may become a prototype of a new class of antidepressant drugs. Such compounds will not function by blocking 5-HT reuptake, as many of the currently used drugs, but through a direct interaction with the 5-HT₇ receptor. This type of action is highly selective and usually does not require the occurrence of adaptive changes in neuronal functions, thus allowing for a much quicker therapeutic effect.

Key words:

antidepressants, brain slices, frontal cortex, hippocampus, model of stress, serotonin receptors

Abbreviations: 5-HT – 5-hydroxytryptamine, serotonin, CNS – central nervous system, DRN – dorsal raphe nuclei, I(h) – hyperpolarization-activated current, sAHP – slow afterhyperpolarizing potential, SCN – suprachiasmatic nucleus, SSRI – selective serotonin reuptake inhibitor(s)

Introduction

Serotonin (5-hydroxytryptamine, 5-HT) is involved in a variety of physiological and cognitive processes in-

cluding sleep, sensory perception, motor activity, temperature regulation, appetite, hormone secretion, nociception and sexual behavior [40]. In the central nervous system (CNS), serotonin activates numerous 5-HT receptors which have been classified as belonging to seven families and 15 subtypes, on the basis of their pharmacological properties, coupling to intracellular signaling cascades and protein structure [38]. With the exception of the 5-HT₃ receptor, being a ligand-gated ion channel, the remaining ones belong to the class of G-protein coupled metabotropic receptors. However, their diversity, interactions with other neurotransmitter systems and the fact that some 5-HT receptors subtypes do not yet have a complete functional, biochemical and physiological characteristics, make it difficult to obtain a full description of the functions and roles played by 5-HT in the CNS.

Although the last of the serotonin receptor subtypes, the 5-HT₇ receptor, was identified already almost two decades ago [6, 81, 82], the knowledge of the effects of its activation and functions in the CNS is not yet fully developed. The 5-HT₇ receptor has been implicated in mood regulation, circadian rhythmicity and sleep, the disturbances of which are evident in the course of depressive disorders [36, 88]. Moreover, some antidepressants exhibit a high affinity for this receptor [1, 52]. Since there are reasons to believe that it may be involved in the etiology of mental illnesses, this receptor is presently considered one of the most attractive research targets in this regard [34, 60, 61].

Early research of the functions of 5-HT₇ receptors concentrated on neurons of the hypothalamic suprachiasmatic nuclei (SCN), comprising the “biological clock” in the mammalian brain. *In vitro* [37, 53, 85, 104, 105] as well as *in vivo* [4, 22] animal studies, conducted using nonselective 5-HT₇ receptor agonists, demonstrated that their effects such as phase shifting of circadian rhythms, inhibition of spontaneous activity and inhibition of the light stimulation, were diminished by the selective 5-HT₇ receptor antagonists SB 269970 and DR 4004. Moreover, down-regulation of the 5-HT₇ receptor has been found to occur in rat SCN after chronic treatment with tricyclic antidepressants and the SSRI fluoxetine [63, 84]. The implication of the 5-HT₇ receptor in circadian rhythm phase resetting and the involvement of 5-HT₇ receptor-selective antagonists in altering rapid eye movement (REM) sleep parameters in an opposite pattern to that observed in human patients with clinical

depression, was confirmed in the study conducted on 5-HT₇ receptor knockout mice [35, 60, 89].

Antidepressant drugs currently used in psychiatry are effective only in part of patients and do not always produce a complete cure. A successful therapy requires prolonged administration of the drug, which often causes a number of onerous (and sometimes hazardous to health) side-effects [46]. Therefore, an extensive search for new, more effective and safe antidepressant drugs is still to be carried out. Two research groups have shown an antidepressant-like action of the 5-HT₇ receptor antagonist SB 269970 in animal models of depression: the forced swim and tail suspension tests [35, 101]. Interestingly, the data suggest that the 5-HT₇ receptor antagonist, SB 269970, raises the level of 5-HT in brain structures thought to be involved in the pathophysiology of depression i.e., hippocampus, frontal cortex and dorsal raphe nuclei (DRN) [101], but the mechanism of this effect is unclear, since 5-HT₇ receptors are expressed both in the DRN as well as in brain structures which receive the serotonergic innervation [33, 56, 80]. Generally, the available data indicate that activation of 5-HT₇ receptors leads to an increase in the excitability of neurons on which they are localized. For example, experiments conducted on the anterodorsal thalamic neurons have demonstrated that 5-HT₇ receptors mediate membrane depolarization *via* an increase of the hyperpolarization-activated current I(h) [16, 17]. Similarly, the 5-HT₇ receptor-dependent modulation of I(h) is also one of suggested mechanism of the increase of the excitability in rat dorsal root ganglion neurons [14]. The stimulatory effect of the activation of 5-HT₇ receptors on synaptic transmission has also been shown in deep dorsal horn neurons [27]. It has been speculated that 5-HT₇ receptor antagonist-induced increase in brain serotonin release is due to a complex GABA-glutamatergic-serotonergic interaction in the DRN [33, 43, 80] and it has been suggested that 5-HT release may be mediated *via* blockade of 5-HT₇ receptors localized on GABAergic interneurons in the DRN [21]. The studies conducted by Roberts et al. [80] and Glass et al. [29] have suggested that 5-HT₇ receptors in the DRN are localized, among others, on GABAergic cells. However, mainly due to the lack of selective agonists, there are no detailed characteristics of the effects of activation and blockade of the 5-HT₇ receptor in those brain structures, which are thought to be most important in the context of pathophysiology of affective disorders.

The effects of 5-HT₇ receptor activation on hippocampal excitatory and inhibitory neurons and synaptic connections

In order to get insight into the role played in normal conditions by the 5-HT₇ receptor in excitatory and inhibitory neurons of the hippocampus, a brain structure receiving a massive serotonergic innervation, the effects of the activation of this receptor were investigated in the CA1 area using whole-cell recording in rat *in vitro* brain slices. Due to a lack of a selective 5-HT₇ receptor agonist, in order to activate 5-HT₇ receptors a wider-spectrum serotonin agonist 5-CT was applied in the presence of WAY 100635, a selective 5-HT_{1A} receptor antagonist, the latter being introduced into the slice incubation medium at least 1 h before 5-CT. The results indicate that the 5-HT₇ receptor increases the excitability of excitatory, pyramidal neurons *via* a reduction in the amplitude of the slow after-hyperpolarizing potential (sAHP), an attenuation of the spike frequency adaptation and 2 to 6 mV depolarization [97]. The mechanism of the 5-HT₇ receptor-mediated decrease of sAHP and the reduction of the spike frequency adaptation has been attributed to the inhibition of Ca²⁺-activated K⁺ channels (K_{AHP}). Earlier research from this laboratory demonstrated that these channels play an important role in modulation of excitability of CA1 pyramidal neurons [9]. It has been shown that numerous types of excitatory receptors (a.o., 5-HT₄, β -adrenergic, muscarinic, histaminic, metabotropic glutamate mGluR1) close potassium channels of this type. It appears that these channels are deactivated *via* phosphorylation, mainly by the protein kinase A (PKA), but also by the protein kinase C (PKC) [9]. The findings reported by other researchers confirm that 5-HT₇ receptors modulate the excitability of hippocampal pyramidal neurons of the CA3 area by closing potassium channels of the K_{AHP} type [5].

The activity of hippocampal excitatory, pyramidal neurons remains under control of GABAergic feed-forward or feed-back connections [24, 25]. It has been suggested that the activation of 5-HT₇ receptors modulates the function of GABAergic interneurons in the raphe nuclei [80]. The activation of 5-HT₇ receptors enhances the excitability of GABAergic neurons in globus pallidus [18] but 5-HT₇ receptors decrease GABA-dependent currents in the SCN [43]. Therefore, we examined the effect of the activation of

5-HT₇ receptors on GABAergic, spontaneous postsynaptic inhibitory currents (sIPSCs) recorded from CA1 pyramidal neurons.

The activation of 5-HT₇ receptors increased the mean sIPSCs frequency while the mean sIPSCs amplitude remained unchanged [93]. An increased frequency of spontaneous postsynaptic currents reflects either the enhanced firing of presynaptic cells, or increased neurotransmitter release and/or changes in the number of neurotransmitter release sites. Hence, several mechanisms may potentially account for the observed 5-HT₇ receptor-dependent enhancement of GABA release. It is conceivable that 5-HT₇ receptor activation directly raises the excitability of interneurons and/or increases the release of GABA *via* activation of 5-HT₇ receptors located on presynaptic terminals. Alternatively, the enhanced release of GABA may be an indirect consequence of the increased glutamatergic, excitatory input to GABAergic cells due to activation of 5-HT₇ receptors located in the perisomatic region of glutamatergic neurons. Immunohistochemical studies have demonstrated the presence of 5-HT₇ receptors on the cell bodies of pyramidal neurons in the CA1 area [8]. Indeed, successive experiments indicated an increase in the frequency of sEPSCs recorded from interneurons after 5-CT application [93]. Furthermore, after the blockade of glutamatergic transmission by the nonselective antagonist, kynurenic acid [26, 74], the magnitude of 5-HT₇ receptor-induced effect on the frequency of sIPSCs recorded from pyramidal cells was significantly weaker [93]. Hence, the above data suggest that 5-HT₇ receptor-induced increase in GABA release is partly due to the increased excitatory input to GABAergic neurons.

Another mechanism underlying the stimulatory effect of 5-HT₇ receptor activation on sIPSCs frequency seems to operate through 5-HT₇ receptors localized on GABAergic cells. To the best of our knowledge, there are no data which would confirm the expression of these receptors in hippocampal interneurons. However, several authors have concluded that 5-HT₇ receptors are expressed, for example, in GABAergic cells in the DRN [20, 21, 29, 80]. The increase in interneuron firing rate cannot account for the observed effect on sIPSCs frequency, as no 5-CT-induced changes in GABAergic interneuron excitability have been reported [93]. Moreover, in the presence of kynurenic acid and, additionally, TTX, the sodium channel blocker, activation of 5-HT₇ receptors still in-

duced an increase in sIPSCs frequency [93]. Thus, it seems conceivable that 5-HT₇ receptors modulate the release of GABA from axon terminals. Further studies using immunochemical methods are necessary to verify the expression of 5-HT₇ receptors on hippocampal GABAergic interneurons.

The influence of corticosterone and antidepressant drugs on the reactivity of the 5-HT₇ receptor in hippocampal neurons

Our earlier experiments have shown that electroconvulsive therapy (ECS) and repeated administration of antidepressants (imipramine, citalopram) increase the inhibitory effect of 5-HT in the hippocampus *via* two mechanisms: (a) the increased response to the activation of inhibitory 5-HT_{1A} receptors and (b) the diminished effect of activation of excitatory 5-HT₄ receptors [10, 90]. To study the influence of antidepressant drugs on the effect of activation of 5-HT₇ receptors, our laboratory used the measurements of spontaneous epileptiform bursts, recorded from the CA3 hippocampal area under nominally Mg²⁺-free incubation conditions in rat *in vitro* brain slices. Activation of 5-HT₇ receptors induced an increase in the frequency of spontaneous epileptiform bursts, recorded from the CA3 area under nominally Mg²⁺-free incubation conditions, was increased after 5-CT application [96]. In this experimental model, repeated treatment with the SSRI, citalopram, or the tricyclic antidepressant, imipramine, resulted in attenuation of the excitatory effects of activation of hippocampal 5-HT₇ receptors [96].

The repeated stressors often cause a variety of disturbances and irregularities in the cognitive, emotional and physiological processes of the organism [58, 107]. A chronic high level of corticosteroid hormones (cortisol in humans and corticosterone in rodents) leads to hyperactivity [77], deregulation of the functions of the hypothalamus-pituitary-adrenal (HPA) axis and disrupts the mechanism of the HPA axis negative feedback [64, 87]. Since a prolonged elevation of plasma cortisol level often occurs in the course of depressive disorders in human patients, it has been commonly accepted that long-lasting alterations in the activity of the HPA axis are a risk factor to the precipitation of the disease [71]. Repeated corticosterone administration has often been used as an animal model for studying the effects of prolonged stress and

a role of stress in depression [86, 100, 109]. It has been shown that corticosterone injections repeated for 21 days increased the percentage of immobility time and decreased the percentage of swimming time in a forced swim test; those two effects being commonly regarded as a depression-like behavior in rats [31]. A specific advantage of this model is the elimination of the adaptation of the organism to a repeated stressor [64, 65, 77]. An earlier study from this laboratory showed that repeated corticosterone administration caused changes in the reactivity of 5-HT_{1A} and 5-HT₄ receptors in the CA1 area of the hippocampus, which were reversed by a simultaneous treatment with imipramine [108]. Testing the effects of the activation of 5-HT₇ receptors has proven that repeated corticosterone administration increased the reactivity of rat CA3 hippocampal circuitry to the activation of this receptor. Moreover, it has been demonstrated that imipramine, administered concurrently with corticosterone, counteracted changes occurring due to corticosterone. It has also been shown that in rats treated with corticosterone and imipramine, the functional modification in the reactivity of 5-HT₇ receptors was not accompanied with changes in the binding of the selective ligand [³H]SB 269970 [95]. These results suggest that imipramine and corticosterone treatments modify neither the number of receptors nor their binding properties but they influence in an opposite manner the signaling cascades downstream the receptor. These modifications are likely to involve changes in the capacity of the receptor to activate G protein and/or changes in G protein expression or phosphorylation [15, 50, 69]. These data are consistent with the results obtained by other investigators who demonstrated that multiple ECS, lithium and fluoxetine reduced the quantity of mRNA for the α subunit of the Gs protein in the CA1 hippocampal area [48, 59], while fluoxetine, imipramine, clomipramine, desimipramine and clorgyline also reduced the protein amount of the α subunit of the Gs [50, 49].

The influence of the blockade of the hippocampal 5-HT₇ receptor on its reactivity

Recent research has demonstrated a synergistic interaction between compounds acting as 5-HT receptor antagonists and several antidepressant drugs, including the specific 5-HT₇ receptor antagonist SB 269970.

Moreover, inactivation and blockade of the 5-HT₇ receptor have been shown to induce antidepressant-like behavioral effects in animal models [32, 35, 101, 102]. Several psychotropic drugs exhibit a high affinity for 5-HT₇ receptors [52]. Our earlier study indicated an attenuation of the effects of the activation of 5-HT₇ receptors in rat hippocampus after treatment with the antidepressant drugs, imipramine and citalopram [96]. Collectively, these findings support the hypothesis that one important mechanism of the therapeutic effects of chronic treatment with antidepressants may be related to the blockade of the 5-HT₇ receptor.

Since only acute administration of the 5-HT₇ receptor antagonist SB 269970 has been investigated before, we set up to examine and compare the effects of acute and prolonged treatment with SB 269970 on the reactivity of the 5-HT₇ receptor using a biochemical and electrophysiological approach. The obtained results showed that both acute and repeated treatment with SB 269970 decreased the reactivity of the 5-HT₇ receptor assessed with the use of the recording of spontaneous epileptiform activity in the hippocampal CA3 area under nominally Mg²⁺-free incubation conditions [98]. The mechanisms underlying the observed attenuation of the excitatory effect of the 5-HT₇ receptor activation by SB 269970 may potentially be related to either the decreased receptor density or the modification in the capacity of the receptor to activate G protein, changes in G protein expression or phosphorylation, or modifications at the level of effectors. The data demonstrated that both single and repeated SB 269970 administration lowered the level of mRNA of those G proteins (*Gas* and *Ga12*) which couple to the 5-HT₇ receptor in the hippocampus [103]. Repeated treatment with SB 269970 also decreased the density of 5-HT₇ receptors [98]. These effects differed markedly from the effects of the antidepressant imipramine, which altered neither the level of the mRNAs nor the density of 5-HT₇ receptors when administered once or repeatedly for 14 days. Also, in contrast to imipramine, repeated SB 269970 administration decreased the mean basal bursting frequency in hippocampal slices. The most likely explanation of this phenomenon is a reduction of excitatory synaptic transmission due to SB 269970 treatment. These results indicate that changes induced by the administration of SB 269970 depend, at least in part, on the mechanisms which are different from those underlying the effects of the antidepressant drug imipramine.

Besides modulation of membrane excitability, activation of hippocampal 5-HT₇ receptors has been shown to stimulate neurite outgrowth [47]. Both *Gas* and *Ga12* proteins can regulate cellular morphology by activating different signaling cascades. *Gas* protein-mediated morphogenic effects are produced by either modulation of cAMP concentration [19] or a direct binding of the *Gas* protein to the cytoskeleton [106]. Downstream *Ga12* protein effectors, which mediate changes in the actin cytoskeleton, are members of the Rho family of small GTPases, including RhoA, Rac1 and Cdc42 [41]. The major functional effects of this pathway include actin reorganization and the formation of neurite-like protrusions and are mediated by the activation of Cdc42 [47]. It is proposed that the activation of the 5-HT₇ receptor by *Gas* and *Ga12* proteins may stimulate glutamatergic synaptic transmission by a positive influence on a number of functional synapses. Hence, the prolonged blockade of the 5-HT₇ receptor, resulting in a decreased expression of *Gas* and *Ga12* proteins, might account for the observed reduction of glutamatergic transmission.

Thus, the experiments showed that the blockade of the 5-HT₇ receptor by SB 269970 led to a functional desensitization of the 5-HT₇ receptor system at the level of effector proteins, although we note that changes in the receptor density occurred after chronic treatment with the antagonist. The phenomenon of 5-HT₇ receptor system downregulation may be an important factor in the mechanism of the antidepressant effect of the 5-HT₇ antagonist, as well as in the modulation of reactivity of other neurotransmitter systems.

The influence of antidepressant drugs and the blockade of 5-HT₇ receptors on glutamatergic transmission in rat frontal cortex

Emotional and cognitive processes, which are disrupted in course of affective disorders, depend on the limbic areas of the brain. The limbic system is connected with the frontal cortex, a part of the cerebral cortex responsible for the integration of emotional reactions with cognitive processes and the control of behavior. The abnormalities in cognitive functions and emotional behavior occurring during depressive disorders implicate the involvement of the frontal cortex in the pathophysiology of depression and in the action of antidepressant drugs [44, 45, 55].

A growing body of evidence indicates that abnormalities in the glutamatergic transmission play an important role in the pathophysiology of mood disorders, and that the common mechanism of antidepressant therapies involves modifications in the function of the glutamatergic system [46, 70, 72]. The unmet need for an improved pharmacotherapy of treatment-resistant depression has resulted in a search for new compounds with new mechanisms of action such as those expressing affinity for glutamate receptors [7, 42, 54, 70]. It has been shown that N-methyl-D-aspartate (NMDA) receptor antagonists exhibit antidepressant-like actions in animal behavioral models and potentiate the effects of antidepressants [99]. It has also been established that chronic treatment with various antidepressants results in a reduction of the radioligand binding to rat cortical NMDA receptors [66, 67]. On the basis of these findings it has been hypothesized that the mechanism of antidepressant action is related to the attenuated function of NMDA receptors in the cerebral cortex [75, 83]. According to the glutamate hypothesis of depression, the glutamatergic system is a primary mediator of psychiatric pathology and, potentially, also a final common pathway for the therapeutic action of antidepressants [3, 39, 46].

Despite a substantial body of evidence indicating the involvement of adaptive changes in the function of NMDA receptors during antidepressant therapies, no attempts have yet been made to assess changes in cortical glutamatergic receptor functions using an electrophysiological approach. Therefore, we aimed at finding effects of repeated administration of the tricyclic antidepressant, imipramine, on glutamatergic transmission in rat frontal cortex using whole-cell recording. Since our previous study showed that serotonin, acting *via* 5-HT₇ receptors, exerted significant modulatory influence on synaptic transmission in rat hippocampus, it was conceivable that the antidepressant-like effects of the 5-HT₇ receptor antagonist may be related to its modulatory action on glutamatergic transmission also in the cortex. Therefore, we also investigated the effects of single and repeated administration of the 5-HT₇ antagonist SB 269970 on glutamatergic neurons and excitatory synaptic transmission in slices of the rat cortex. Our study showed that repeated administration of imipramine and SB 269970 strongly reduced the mean frequency and, to a smaller extent, the mean amplitude of sEPSCs recorded from layer II/III cortical pyramidal neurons 2 days after termination of the treatment [94, 92].

Frontal cortex receives a dense serotonergic input from the DRN [68]. Being released from axon terminals of the raphe neurons, serotonin has been shown to affect the action of several neurotransmitters by the heterosynaptic activation of 5-HT receptors located on neighboring axon terminals [23]. The heterosynaptic activation of 5-HT receptors on glutamatergic neurons has been shown to inhibit or stimulate glutamate release in the cortex *via* 5-HT_{1A}, 5-HT_{1B} or 5-HT_{2A} receptors, respectively [13, 30, 57]. Hence it is conceivable that the decrease in glutamatergic transmission after repeated imipramine or chronic blockade of 5-HT₇ receptors, observed in our study, occurs as a result of the activation of other classes of 5-HT receptors, but not 5-HT₇ receptors, by a prolonged elevation of the 5-HT level in the cortex induced by the blockade of 5-HT₇ receptors in the DRN. So far, only a few studies have examined the effect of SB-269970, administered alone or jointly with antidepressant drugs, on 5-HT release in the cortex. Wesołowska and Kowalska [101] demonstrated that both SB-269970 and imipramine increased the efflux of DA, NA and 5-HT in rat prefrontal cortex. On the other hand, some authors found that SB-269970 significantly inhibited 5-HT efflux [79].

It is well known that the functional changes that occur within the presynaptic terminals affect the frequency of sEPSCs, while the amplitude of postsynaptic currents depends on both presynaptic factors, such as the amount of neurotransmitters in synaptic vesicles, and postsynaptic ones – mainly the number of receptors for the neurotransmitter e.g., [78]. It is conceivable that the observed decrease in the frequency of sEPSCs may potentially result from the imipramine- or SB 269970-induced decrease in the spontaneous firing of cells synapsing on neurons from which the recording was made. However, all recorded cells showed no spontaneous spiking during the initial current-clamp recording at the resting membrane potential. Moreover, the lack of a significant change in the mean frequency of sEPSC after the blockade of Na channels in the tested sample of neurons suggested that a majority of recorded sEPSCs corresponded to miniature EPSCs whose frequency is not related to the spiking activity of presynaptic cell. Hence, an approximately two-fold decrease in the sEPSC mean frequency, observed in the present study, resulted from the diminution of glutamate release [51].

The observed reduction in the mean amplitude of sEPSCs may principally result from changes in the membrane resistance, however, neither imipramine

nor SB 269970 affected the basic electrophysiological parameters of the recorded neurons (input resistance, resting membrane potential and excitability). The comparison between the NMDA and the AMPA/kainate receptor-mediated electrically evoked EPSCs ratio indicated that, at least in the case of imipramine, chronic treatment led to a relative reduction of the NMDA receptor-mediated response and/or decrease in its density [92].

The effects of repeated stress and the 5-HT₇ receptor antagonist on long-term potentiation in rat frontal cortex

Memory disturbances belong to the most common symptoms of depression and other illnesses caused by repeated stress or traumatic experiences. For example, repeated restraint stress has been shown to induce a strong desensitization of the hypothalamic-pituitary-adrenal axis and an elevation of plasma corticosterone level e.g., [28]. Long-term potentiation (LTP) of synaptic transmission is an experimental model of cellular and molecular changes that seem to underlie the formation and maintenance of memory traces in the brain. The processes involved in the induction and maintenance of LTP are still not fully understood, but an external manifestation of this phenomenon, i.e., the activity-dependent increase in the efficiency of synaptic connections lasting for several weeks, is an example of the strengthening of synaptic connection, depending on simultaneous pre- and postsynaptic activity. LTP has been shown to be suppressed by repeated stress [2, 73]. It has been well documented that, in general, chronic stress disrupts neural plasticity, while antidepressant drugs produce an opposite effect [76].

We investigated the effect of repeated restraint stress on glutamatergic field potentials and LTP in rat frontal cortex. The animals were subjected to restraint lasting 10 min twice daily for 3 days. The 5-HT₇ receptor antagonist SB 269970 was administered before each restraint stress session and would prevent the occurrence of changes induced by repeated exposure to stress. The obtained data indicate that the 5-HT₇ receptor antagonist SB 269970 prevents the occurrence of the restraint stress-induced enhancement of glutamatergic transmission and attenuation of LTP in rat frontal cortex [91]. We also demonstrated that re-

peated corticosterone treatment enhances excitatory synaptic transmission and impairs LTP in rat frontal cortex, whereas the tricyclic antidepressant imipramine, administered jointly with corticosterone, normalizes the enhanced basal excitatory synaptic transmission and the reduced potential for long-term synaptic plasticity, evoked by repeated corticosterone administration [11]. Intraperitoneal administration of SB-269970 raises the extracellular levels of serotonin as well as these of dopamine, noradrenaline in rat prefrontal cortex, thus resembling the effect of administration of antidepressant drugs [12, 33, 101]. It may be hypothesized that the elevated level of 5-HT and/or noradrenaline compensates the effect of restraint stress on glutamatergic transmission and synaptic plasticity.

Conclusions

The data obtained in the course of studies summarized here indicate that serotonin, by acting through 5-HT₇ receptors, exerts modulatory influence on hippocampal excitatory cells and on glutamate and GABA mediated synaptic transmission in rat hippocampus. Since the prolonged blockade of 5-HT₇ receptors decreases glutamatergic transmission in the frontal cortex in a similar way as does imipramine, and it restores the capacity of cortical excitatory synapses to undergo antagonists of the 5-HT₇ receptor as new substances to be possibly applied in the treatment of affective disorders. Identification of this novel 5-HT₇ receptor-mediated effect seems important to the elucidation of the physiological significance of these receptors. These studies provide new information about the involvement of 5-HT₇ receptors in the mechanisms which allow serotonin to simultaneously remodel neuronal activity in a functionally appropriate manner in a wide variety of cell types and excitatory and inhibitory circuits in the hippocampus.

Acknowledgment:

This study was supported by the Ministry of Science and Higher Education (Warszawa, Poland) grant no. 0259/BP01/2010/38 and grant: POIG 01.01.02-12-004/09-00 financed by European Regional Development Fund and by project UDA-POIG.01.03.010-12-100/08-00 (ModAll) co-financed by European Union from the European Fund of Regional Development (EFRD), as well as by the statutory funding from the Institute of Pharmacology, Polish Academy of Sciences, Poland.

References:

1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL: Amisulpride is a potent 5-HT₇ antagonist: relevance for antidepressant actions in vivo. *Psychopharmacology (Berl)*, 2009, 205, 119–128.
2. Alfarez DN, Joëls M, Krugers HJ: Chronic unpredictable stress impairs long-term potentiation in rat hippocampal CA1 area and dentate gyrus in vitro. *Eur J Neurosci*, 2003, 17, 1928–1934.
3. Alt A, Nisenbaum ES, Bleakman D, Witkin JM: A role for AMPA receptors in mood disorders. *Biochem Pharmacol*, 2007, 71, 1273–1288.
4. Antle MC, Ogilvie MD, Pickard GE, Mistlberger RE: Response of the mouse circadian system to serotonin 1A/2/7 agonists in vivo: surprisingly little. *J Biol Rhythms*, 2003, 18, 145–158.
5. Bacon WL, Beck SG: 5-Hydroxytryptamine₇ receptor activation decreases slow afterhyperpolarization amplitude in CA3 hippocampal pyramidal cells. *J Pharmacol Exp Ther*, 2000, 294, 672–679.
6. Bard A, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL: Cloning of a novel human serotonin receptor (5-HT₇) positively linked to adenylate cyclase. *J Biol Chem*, 1993, 268, 23422–23426.
7. Bermack J, Lavoie N, Dryver E, Debonnel G: Effects of sigma ligands on NMDA receptor function in the bulbectomy model of depression: a behavioural study in the rat. *Int J Neuropsychopharmacol*, 2002, 5, 53–62.
8. Bickmeyer U, Heine M, Mancke T, Richter DW: Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons. *Eur J Neurosci*, 2002, 16, 209–218.
9. Bijak M, Misgeld U: Effects of serotonin through serotonin_{1A} and serotonin₄ receptors on inhibition in the guinea-pig dentate gyrus in vitro. *Neuroscience*, 1997, 78, 1017–1026.
10. Bijak M, Tokarski K, Maj J: Repeated treatment with antidepressant drugs induces subsensitivity to the excitatory effect of 5-HT₄ receptor activation in the rat hippocampus. *Naunyn Schmiedeberg's Arch Pharmacol*, 1997, 355, 14–19.
11. Bobula B, Wabno J, Hess G: Imipramine counteracts corticosterone-induced enhancement of glutamatergic transmission and impairment of long-term potentiation in rat frontal cortex. *Pharmacol Rep*, 2011, 63, 1404–1412.
12. Bonaventure P, Kelly L, Aluisio L: Selective blockade of 5-hydroxytryptamine (5-HT)₇ receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. *J Pharmacol Exp Ther*, 2007, 321, 690–698.
13. Calcagno E, Carli M, Invernizzi RW: The 5-HT_{1A} receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. *J Neurochem*, 2006, 96, 853–860.
14. Cardenas CG, Mar LP, Vysokanov AV, Arnold PB, Cardenas LM, Surmeier DJ, Scroggs RS: Serotonergic modulation of hyperpolarization-activated current in acutely isolated rat dorsal root ganglion neurons. *J Physiol*, 1999, 518, 507–523.
15. Castro EM, Diaz A, del Olmo E, Pazos A: Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT_{1A} receptors in rat brain. *Neuropharmacology*, 2003, 44, 93–101.
16. Chapin EM, Andrade R: A 5-HT₇ receptor-mediated depolarization in the anterodorsal thalamus. I. Pharmacological characterization. *J Pharmacol Exp Ther*, 2001, 297, 395–402.
17. Chapin EM, Andrade R: A 5-HT₇ receptor-mediated depolarization in the anterodorsal thalamus. II. Involvement of the hyperpolarization-activated current I(h). *J Pharmacol Exp Ther*, 2001, 297, 403–409.
18. Chen L, Yung KK, Chan YS, Yung WH: 5-HT excites globus pallidus neurons by multiple receptor mechanisms. *Neuroscience*, 2008, 151, 439–451.
19. Corset V, Nguyen-Ba-Charvet KT, Forcet C, Moyse E, Chédotal A, Mehlen P: Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A_{2b} receptor. *Nature*, 2000, 407, 747–750.
20. Doly S, Fischer J, Brisorgueil M-J, Vergé D, Conrath M: Pre- and postsynaptic localization of the 5-HT₇ receptor in rat dorsal spinal cord: immunocytochemical evidence. *J Comp Neurol*, 2005, 490, 256–269.
21. Duncan MJ, Temel S, Jennes L: Localisation of serotonin 5-HT₇ receptor immunoreactivity in the rat brain. *Soc Neurosci Abstr*, 2001, 380, 18.
22. Ehlen JC, Grossman GH, Glass JD: In vivo resetting of the hamster circadian clock by 5-HT₇ receptors in the suprachiasmatic nucleus. *J Neurosci*, 2001, 21, 5351–5357.
23. Fink KB, Gothert M: 5-HT receptor regulation of neurotransmitter release. *Pharmacol Rev*, 2007, 59, 360–417.
24. Freund TF: Interneuron diversity series: rhythm and mood in perisomatic inhibition. *Trends Neurosci*, 2003, 26, 489–495.
25. Freund TF, Buzsáki GL: Interneurons of the hippocampus. *Hippocampus*, 1996, 6, 347–470.
26. Ganong AH, Cotman CW: Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus. *J Pharmacol Exp Ther*, 1986, 236, 293–299.
27. Garraway SM, Hochman S: Pharmacological characterization of serotonin receptor subtypes modulating primary afferent input to deep dorsal horn neurons in the neonatal rat. *Br J Pharmacol*, 2001, 132, 1789–1798.
28. Gadek-Michalska A, Bugajski J: Repeated handling, restraint, or chronic crowding impair the hypothalamic-pituitary-adrenocortical response to acute restraint stress. *J Physiol Pharmacol*, 2003, 54, 449–459.
29. Glass JD, Grossman GH, Farnbauch L, DiNardo L: Mid-brain raphe modulation of nonphotic circadian clock resetting and 5-HT release in the mammalian suprachiasmatic nucleus. *J Neurosci*, 2003, 23, 7451–7460.
30. Gołmbiowska K, Dziubina A: Inhibition of amino acid release by 5-HT_{1B} receptor agonist in the rat prefrontal cortex. *Pol J Pharmacol*, 2002, 54, 625–631.
31. Gregus A, Wintink AJ, Davis AC, Kalynchuk LE: Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. *Behav Brain Res*, 2005, 156, 105–114.
32. Guscott M, Bristow LJ, Hadingham K, Rosahl TW, Beer MS, Stanton JA, Bromidge F et al.: Genetic knockout and pharmacological blockade studies of the 5-HT₇ re-

- ceptor suggest therapeutic potential in depression. *Neuropharmacology*, 2005, 48, 492–502.
33. Harsing LG, Prauda I, Barkoczy J, Matyus P, Juranyi Z: A 5-HT₇ heteroreceptor-mediated inhibition of [³H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction. *Neurochem Res*, 2004, 29, 1487–1497.
 34. Hedlund PB: The 5-HT₇ receptor and disorders of the nervous system: an overview *Psychopharmacology (Berl)*, 2009, 206, 345–354.
 35. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG: 5-HT₇ receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. *Biol Psychiatry*, 2005, 58, 831–837.
 36. Hedlund PB, Sutcliffe JG: Functional, molecular and pharmacological advances in 5-HT₇ receptor research. *Trends Pharmacol Sci*, 2004, 25, 481–486.
 37. Horikawa K, Yokota S, Fuji K, Akiyama M, Moriya T, Okamura H, Shibata S: Nonphotic entrainment by 5-HT_{1A/7} receptor agonists accompanied by reduced *Per1* and *Per2* mRNA levels in the suprachiasmatic nuclei. *J Neurosci*, 2000, 20, 5867–5873.
 38. Hoyer D, Hannon JP, Martin GR: Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol Biochem Behav*, 2002, 71, 533–554.
 39. Iyo AH, Feyissa AM, Chandran A, Austin MC, Regunathan S, Karolewicz B: Chronic corticosterone administration down-regulates metabotropic glutamate receptor 5 protein expression in the rat hippocampus. *Neuroscience*, 2010, 169, 1567–1574.
 40. Jacobs BL, Azmitia EC: Structure and function of the brain serotonin system. *Physiol Rev*, 1992, 72, 165–229.
 41. Jaffe AB, Hall A: Rho GTPases: biochemistry and biology. *Annu Rev Cell Dev Biol*, 2005, 21, 247–269.
 42. Jin R, Clark S, Weeks AM, Dudman JT, Gouaux E, Partin KM: Mechanism of positive allosteric modulators acting on AMPA receptors. *J Neurosci*, 2005, 25, 9027–9036.
 43. Kawahara F, Saito H, Katsuki H: Inhibition by 5-HT₇ receptor stimulation of GABAA receptor-activated current in cultured rat suprachiasmatic neurones. *J Physiol*, 1994, 478, 67–73.
 44. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML: The neural correlates of anhedonia in major depressive disorder. *Biol Psychiatry*, 2005, 58, 843–853.
 45. Krishnan V, Nestler EJ: Molecular neurobiology of depression. *Nature*, 2008, 455, 894–902.
 46. Kugaya A, Sanacora G: Beyond monoamines: glutamatergic function in mood disorders. *CNS Spectr*, 2005, 10, 808–819.
 47. Kvachnina E, Liu G, Dityatev A, Renner U, Dumuis A, Richter DW, Dityateva G: 5-HT₇ receptor is coupled to G α subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. *J Neurosci*, 2005, 25, 7821–7830.
 48. Lesch KP, Aulakh CS, Tolliver TJ, Hill JL, Murphy DL: Regulation of G proteins by chronic antidepressant drug treatment in rat brain: tricyclics but not clorgyline increase G α subunits. *Eur J Pharmacol*, 1991, 207, 361–364.
 49. Lesch KP, Aulakh CS, Wolozin BL, Murphy DL: Serotonin (5-HT) receptor, 5-HT transporter and G protein-effector expression: implications for depression. *Pharmacol Toxicol*, 1992, 71, 49–60.
 50. Lesch KP, Manji HK: Signal-transducing G proteins and antidepressant drugs: evidence for modulation of alpha subunit gene expression in rat brain. *Biol Psychiatry*, 1992, 32, 549–579.
 51. Li H, Prince DA: Synaptic activity in chronically injured, epileptogenic sensory motor neocortex. *J Neurophysiol*, 2002, 88, 2–12.
 52. López-Rodríguez ML, Benhamú B, Morcillo MJ, Porras E, Lavandera JL, Pardo L: Serotonin 5-HT₇ receptor antagonists. *Curr Med Chem Cent Nerv Syst Agents*, 2004, 4, 203–214.
 53. Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, Foye PE, Racke M: A novel adenylyl cyclase-activating serotonin receptor (5-HT₇) implicated in the regulation of mammalian circadian rhythms. *Neuron*, 1993, 11, 449–458.
 54. Mackowiak M, O'Neill MJ, Hicks CA, Bleakman D, Skolnick P: An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo study. *Neuropharmacology*, 2002, 43, 1–10.
 55. Manji HK, Drevets WC, Charney DS: The cellular neurobiology of depression. *Nat Med*, 2001, 7, 541–547.
 56. Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P: Role of the 5-HT₇ receptor in the central nervous system: from current status to future perspectives. *Mol Neurobiol*, 2011, 43, 228–253.
 57. Maura G, Marcoli M, Tortarolo M, Andrioli M, Raiteri M: Glutamate release in human cerebral cortex and its modulation by 5-hydroxytryptamine acting at 5-HT_{1D} receptors. *Br J Pharmacol*, 1998, 123, 45–50.
 58. McEwen BS, Sapolsky RM: Stress and cognitive function. *Curr Opin Neurobiol*, 1995, 5, 205–216.
 59. McGowan S, Eastwood SL, Mead A, Burnet PW, Smith C, Flanagan TP, Harrison PJ: Hippocampal and cortical G protein (G α , G α and G α) mRNA expression after electroconvulsive shock or lithium carbonate treatment. *Eur J Pharmacol*, 1996, 306, 249–255.
 60. Monti JM, Jantos H: Effects of the 5-HT₇ receptor antagonist SB-269970 microinjected into the dorsal raphe nucleus on REM sleep in the rat. *Behav Brain Res*, 2006, 167, 245–250.
 61. Mnie-Filali O, Lambas-Señas L, Scarna H, Haddjeri N: Therapeutic potential of 5-HT₇ receptors in mood disorders. *Curr Drug Targets*, 2009, 10, 1109–1117.
 62. Mnie-Filali O, Lambás-Señas L, Zimmer L, Haddjeri N: 5-HT₇ receptor antagonists as a new class of antidepressants. *Drug News Perspect*, 2007, 20, 613–618.
 63. Mullins UL, Gianutsos G, Eison AS: Effects of antidepressants on 5-HT₇ receptor regulation in the rat hypothalamus. *Neuropsychopharmacology*, 1999, 21, 352–367.
 64. Murray F, Smith DV, Hutson PH: Chronic low dose corticosterone exposure decreased hippocampal cell proliferation, volume and induced anxiety and depression like behaviours in mice. *Eur J Pharmacol*, 2008, 583, 115–127.
 65. Nestler EJ, Hyman SE: Animal models of neuropsychiatric disorders. *Nature Neurosci*, 2010, 13, 1161–1169.
 66. Nowak G, Li Y, Paul IA: Adaptation of cortical but not hippocampal NMDA receptors after chronic citalopram treatment. *Eur J Pharmacol*, 1996, 295, 75–85.

67. Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA: Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. *J Pharmacol Exp Ther*, 1993, 265, 1380–1386.
68. O'Hearn E, Molliver ME: Organization of raphe-cortical projections in rat: a quantitative retrograde study. *Brain Res Bull*, 1984, 13, 709–726.
69. Okuhara DY, Beck SG, Muma NA: Corticosterone alters G protein α -subunit levels in the rat hippocampus. *Brain Res*, 1997, 745, 144–151.
70. Palucha A, Pilc A: The involvement of glutamate in the pathophysiology of depression. *Drug News Perspect*, 2005, 18, 262–268.
71. Parker KJ, Schatzberg AF, Lyons DM: Neuroendocrine aspects of hypercortisolism in major depression. *Horm Behav*, 2003, 43, 60–66.
72. Paul IA, Skolnick P: Glutamate and depression: clinical and preclinical studies. *Ann N Y Acad Sci*, 2003, 1003, 250–272.
73. Pavlides C, Nivon LG, McEwen BS: Effects of chronic stress on hippocampal long-term potentiation. *Hippocampus*, 2002, 12, 245–257.
74. Perkins MN, Stone TW: An iontophoretic investigation of the actions of convulsant kynurenes and their interaction with the endogenous excitant quinolinic acid. *Brain Res*, 1982, 247, 184–187.
75. Petrie RXA, Reid IC, Stewart CA: The N-methyl-D-aspartate receptor, synaptic plasticity and depressive disorder. *Pharmacol Therapeut*, 2000, 87, 11–25.
76. Pittenger C, Duman RS: Stress, depression, and neuroplasticity: a convergence of mechanisms. *Neuropsychopharmacology*, 2008, 33, 88–109.
77. Raone A, Cassanelli A, Scheggi S, Rauggi R, Danielli B, De Montis MG: Hypothalamus-Pituitary-Adrenal modifications consequent to chronic stress exposure in an experimental model of depression in rats. *Neuroscience*, 2007, 146, 1734–1742.
78. Ren W, Palazzo E, Maione S, Neugebauer V: Differential effects of mGluR7 and mGluR8 activation on pain-related synaptic activity in the amygdala. *Neuropharmacology*, 2011, 61, 1334–1344.
79. Roberts C, Allen L, Langmead CJ, Hagan JJ, Middlemiss DN, Price GW: The effect of SB-269970, a 5-HT₇ receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. *Br J Pharmacol*, 2001, 132, 1574–1580.
80. Roberts C, Thomas DR, Bate ST, Kew JNC: GABAergic modulation of 5-HT₇ receptor-mediated effects on 5-HT efflux in the quinea-pig dorsal raphe nucleus. *Neuropharmacology*, 2004, 46, 935–941.
81. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC: Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT₇) activating cAMP formation. *Proc Natl Acad Sci USA*, 1993, 90, 8547–8551.
82. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR: Molecular cloning and expression of a 5-hydroxytryptamine₇ serotonin receptor subtype. *J Biol Chem*, 1993, 268, 18200–18204.
83. Skolnick P: Antidepressants for the new millennium. *Eur J Pharmacol*, 1999, 375, 31–40.
84. Sleight AJ, Carolo C, Petit N, Zwingelstein C, Bourson A: Identification of 5-hydroxytryptamine₇ receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. *Mol Pharmacol*, 1995, 47, 99–103.
85. Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A: 8-OH-DPAT as a 5-HT₇ agonist: phase shifts of the circadian biological clock through increases in cAMP production. *Neuropharmacology*, 2004, 46, 52–62.
86. Sterner EY, Kalynchuk LE: Behavioral and neurobiological consequences of prolonged glucocorticoid exposure in rats: Relevance to depression. *Prog Neuropsychopharmacol Biol Psychiatry*, 2010, 34, 777–790.
87. Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G, Hen R, Belzung C: Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant. *Reversal Biol Psychiatry*, 2008, 64, 293–301.
88. Thomas DR, Hagan JJ: 5-HT₇ receptors. *Curr Drug Targets CNS Neurol Disord*, 2004, 3, 81–90.
89. Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, Deeks NJ: SB-656104-A, a novel selective 5-HT₇ receptor antagonist, modulates REM sleep in rats. *Br J Pharmacol*, 2003, 139, 705–714.
90. Tokarski K, Bijak M: Antidepressant-induced adaptive changes in the effects of 5-HT, 5-HT_{1A} and 5-HT₄ agonists on the population spike recorded in hippocampal CA1 cells do not involve presynaptic effects on excitatory synaptic transmission. *Pol J Pharmacol*, 1996, 48, 565–573.
91. Tokarski K, Bobula B, Kusek M, Hess G: The 5-HT₇ receptor antagonist SB 269970 counteracts restraint stress-induced attenuation of long-term potentiation in rat frontal cortex. *J Physiol Pharmacol*, 2011, 62, 663–667.
92. Tokarski K, Bobula B, Wabno J, Hess G: Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. *Neuroscience*, 2008, 153, 789–795.
93. Tokarski K, Kusek M, Hess G: 5-HT₇ receptors modulate GABAergic transmission in rat hippocampal CA1 area. *J Physiol Pharmacol*, 2011, 62, 535–540.
94. Tokarski K, Kusek M, Hess G: Repeated blockade of 5-HT₇ receptors depresses glutamatergic transmission in the rat frontal cortex. *J Physiol Pharmacol*, 2012, 63, 173–177.
95. Tokarski K, Pitra P, Duszynska B, Hess G: Imipramine counteracts corticosterone-induced alterations in the effects of the activation of 5-HT₇ receptors in rat hippocampus. *J Physiol Pharmacol*, 2009, 60, 83–88.
96. Tokarski K, Zahorodna A, Bobula B, Grzegorzewska M, Pitra P, Hess G: Repeated administration of citalopram and imipramine alters the responsiveness of rat hippocampal circuitry to the activation of 5-HT₇ receptors. *Eur J Pharmacol*, 2005, 524, 60–66.
97. Tokarski K, Zahorodna A, Bobula B, Hess G: 5-HT₇ receptors increase the excitability of rat hippocampal CA1 pyramidal neurons. *Brain Res*, 2003, 993, 230–234.
98. Tokarski K, Zelek-Molik A, Duszynska B, Satała G, Bobula B, Kusek M, Chmielarz P et al.: Acute and repeated treatment with the 5-HT₇ receptor antagonist SB

- 269970 induces functional desensitization of 5-HT₇ receptors in rat hippocampus. *Pharmacol Rep*, 2012, 64, 256–265.
99. Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. *Eur J Pharmacol*, 1990, 185, 1–10.
100. Waters P, McCormick CM: Caveats of chronic exogenous corticosterone treatments in adolescent rats and effects on anxiety-like and depressive behavior and hypothalamic-pituitary-adrenal (HPA) axis function. *Biol Mood Anxiety Disord*, 2011, 1, 4–16.
101. Wesołowska A, Kowalska M: Influence of serotonin 5-HT₇ receptor blockade on the behavioral and neurochemical effects of imipramine in rats. *Pharmacol Rep*, 2008, 60, 464–474.
102. Wesołowska A, Tatarczyńska E, Nikiforuk A, Chojnacka-Wójcik E: Enhancement of the anti-immobility action of antidepressants by a selective 5-HT₇ receptor antagonist in the forced swimming test in mice. *Eur J Pharmacol*, 2007, 555, 43–47.
103. Vanhoenacker P, Haegeman G, Leysen JE: 5-HT₇ receptors: current knowledge and future prospects. *Trends Pharmacol Sci*, 2000, 21, 70–77.
104. Ying SW, Rusak B: 5-HT₇ receptors mediate serotonergic effects on light-sensitive suprachiasmatic nucleus neurons. *Brain Res*, 1997, 755, 246–254.
105. Yu GD, Liu YL, Jiang XH, Guo SY, Zhang HQ, Yin QZ, Hisamitsu T: The inhibitory effect of serotonin on the spontaneous discharge of suprachiasmatic neurons in hypothalamic slice is mediated by 5-HT₇ receptor. *Brain Res Bull*, 2001, 54, 395–398.
106. Yu JZ, Dave RH, Allen JA, Sarma T, Rasenick MM: Cytosolic Gas acts as an intracellular messenger to increase microtubule dynamics and promote neurite outgrowth. *J Biol Chem*, 2009, 284, 10462–10472.
107. Yuen EY, Liu W, Karatsoreos IN, Ren Y, Feng J, McEwen BS, Yan Z: Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. *Mol Psychiatry*, 2011, 16, 156–170.
108. Zahorodna A, Tokarski K, Hess G: Imipramine treatment ameliorates corticosterone-induced alterations in the effects of 5-HT_{1A} and 5-HT₄ receptor activation in the CA1 area of rat hippocampus. *Eur Neuropsychopharmacol*, 2006, 16, 383–390.
109. Zhao Y, Ma R, Shen J, Su H, Xing D, Du L: A mouse model of depression induced by repeated corticosterone injections. *Eur J Pharmacol*, 2008, 58, 113–120.

Received: October 10, 2012; **in the revised form:** October 23, 2012;
accepted: October 24, 2012.